Andrew Embleton-Thirsk

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Jonathan A. Ledermann, Andrew Embleton-Thirsk, Fharat Raja et al. · The Lancet · 2016 · 238 citations · Full text

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes

Stefan Kommoss, Boris Winterhoff, Ann L. Oberg et al. · Clinical Cancer Research · 2017 · 136 citations · Full text

Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial

JA Ledermann, Timothy Perren, FA Raja et al. · UCL Discovery (University College London) · 2013 · 102 citations

Azd 2171, Medicine, Metronomic Therapy +9

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

Antonio González-Martı́n, Amit M. Oza, Andrew Embleton-Thirsk et al. · Gynecologic Oncology · 2018 · 61 citations · Full text